12:00 AM
Nov 17, 2014
 |  BioCentury  |  Tools & Techniques

Abcodia's (bio)bankroll

How Abcodia's longitudinal biobank can pinpoint the start of disease

Abcodia Ltd. is hoping therapeutics companies will be able to pinpoint the very start of disease by using the biotech's massive, longitudinal biobank to find out exactly when levels of a marker or target in a seemingly healthy individual begin to deviate from the person's historical baseline.

The biobank contains samples from more than 200,000 postmenopausal women and includes a decade of annual samples from a subset of 50,000 women. The samples were collected in the U.K. Collaborative Trial for Ovarian Cancer Screening (UKCTOCS) by the University College London.

The trial was studying whether ovarian cancer mortality would be lowered by making treatment decisions based on regularly measuring the CA125 biomarker and using an experimental test called ROCA (risk of ovarian cancer algorithm).

Volunteers also gave information about their demographics, lifestyle and disease history. Disease information continues to be collected through an NHS center, as well as through hospital statistics and death certificates.

Abcodia has exclusive rights to the biobank and a first call on IP generated by UCL researchers, who continue to use the samples for their own work.

Abcodia itself is hoping to commercialize the ROCA test for early detection and screening of ovarian cancer. But since opening its doors in 2011, the company has been licensing samples to...

Read the full 1044 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >